Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

citalopram

- PMLiVE

Generic for Lilly’s Evista in US ‘within a month’

Teva to launch copy of osteoporosis drug

- PMLiVE

Five companies breach ABPI code

Lundbeck, A Menarini Pharma, Bayer, HRA Pharma UK and GlaxoSmithKline named by PMCPA

mHealth could be ‘the future’ of healthcare

EC says Europe is preparing for the mHealth revolution

- PMLiVE

More woes for Daiichi as Ranbaxy units stop API shipments

Manufacturing problems continue to gather pace

- PMLiVE

FDA expands efforts to test quality of generics

Monitoring programme to ensure drug copies are equivalent to branded medicines

- PMLiVE

Teva’s Symbicort generic backed for EU approval

AstraZeneca braces for competition to COPD drug

- PMLiVE

Otsuka/Lundbeck say brexpiprazole works in phase III trial

On course as successor to antipsychotic Abilify

- PMLiVE

Actavis sells EU generics businesses to Aurobindo

Divests operations in seven Western European countries

- PMLiVE

Another Ranbaxy plant falls foul of FDA

Indian company violates Good Manufacturing Practice

- PMLiVE

AZ faces early competition to Nexium in the US

Korea's Hanmi and Amneal Pharmaceuticals launches first generic rival

- PMLiVE

Lundbeck names SVP for business development and HR

Jacob Tolstrup is promoted at Danish pharma company

- PMLiVE

Profits down at Lundbeck as revenues slip

Company still feeling effects of Lexapro patent loss

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links